William Slattery
Partner @ Deerfield Capital Management
New York, United States
William Slattery is a funding round investor at Deerfield Capital Management in New York focused on Pharmaceutical and Health Care. William Slattery is based out of New York, New York and is the Partner of Deerfield Management. William previously worked at Amerindo Investment Advisors as a senior healthcare analyst. William Slattery attended the Rutgers University.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries William Slattery invests in
Stages William Slattery invests in
Countries William Slattery invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Pharmaceutical 3 (60%)
- Health Care 2 (40%)
- Biotechnology 2 (40%)
- Medical 1 (20%)
- Biopharma 1 (20%)
Stage
- Funding Round 2 (40%)
- Series A 1 (20%)
- Series B 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Great Lakes Discoveries
|
Great Lakes Discoveries is a company set up by University of Michigan to boost drug commercialisation efforts. | $130M / May 27, 2020 | |
Appello Pharmaceuticals
|
Appello Pharmaceuticals is a Nashville, TN based preclinical-stage company focused on advancing novel positive allosteric modulators of mGlu4 for the treatment of Parkinson’s disease. | Series A / Jun 28, 2018 | |
|
Appello Pharmaceuticals
|
Appello Pharmaceuticals is a Nashville, TN based preclinical-stage company focused on advancing novel positive allosteric modulators of mGlu4 for the treatment of Parkinson’s disease. | Series A / Jun 28, 2018 | |
Bridge Medicines
|
Bridge Medicines is a drug discovery company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management. Bridge Medicines is a groundbreaking initiative that completes anunbroken, fully funded and professionally staffed path from concept to drug candidate, to develop efficiently and quickly innovative therapeutics for the treatment of human diseases. | Oct 31, 2016 | |
Blade Therapeutics
|
Blade Therapeutics is a discovery stage drug development company. Their mission is to create antifibrotic treatment strategies that address a wide variety of congenital and acquired diseases of fibrosis. Their leadership team has extensive experience at developing drugs that treat fibrotic disorders. They are also partnering with internationalexperts in order to identify and in-license cutting-edge technologies to build a robust pipeline of antifibrotic compounds. | $45M / Series B / Jun 16, 2016 |
Co-Investors
Deerfield Capital Management ("DCM") is a global fixed-income investment adviser that has managed institutional, alternative accounts since 1993.
Deerfield Capital Management Contacts
| Name | Phone | Socials | |
|---|---|---|---|
James Flynn
Managing Partner & CEO
|
|||
Jonathan Leff
Partner
|
|||
Lawrence S. Atinsky
Partner
|
|||
Steven Hochberg
Partner
|
|||
|
William Slattery
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does William Slattery invest in?
William Slattery invests primarily in Pharmaceutical, Health Care and Biotechnology startups, most often at Funding Round and Series A stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact William Slattery?
Public channels for William Slattery include LinkedIn and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did William Slattery last invest?
The most recent investment recorded for William Slattery closed in May 2020. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
